Drug Profile
Research programme: liver X receptor modulators - Karo Pharma/Pfizer
Alternative Names: WAY-252623; WAY-254011; WYE-672Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Karo Bio
- Developer Pfizer
- Class Indazoles; Quinolines
- Mechanism of Action Liver X receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atherosclerosis; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Atherosclerosis in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)
- 17 Jul 2012 Due for review, but nothing appears to have changed so just did a quick check. No further publications on google, nothing in Pfizer website but still listed as late research/early preclin for inflammation on Karo website so left dev as is, and added active statement.